Novavax, Inc.

Novavax, Inc.

NVAXNYSE / NASDAQHealthcareSmall cap

$7.47-$0.25 (-3.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.7B
P/E
3.8x
EV / EBITDA
3.4x
Revenue
$1.1B
Net margin
39.2%
ROCE
76.8%

+20.1% over the last year

Novavax, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-34.6%
3M
-11.3%
6M
-19.4%
1Y
+20.1%
5Y
-96.1%

52-week range

Day change -$0.25 (-3.2%) from $7.72 to $7.47 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NVAX, bought on each weekday since 2021.

News & filings

What Novavax filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Return on capital employed of 76.8%.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Read moreShow less

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sector
Healthcare
Shares outstanding
161.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.7B
P/E
3.8x
P/B
-13.1x
EV / EBITDA
3.4x
EV / Sales
1.5x
P/S
1.5x
52-week high
$12.82
52-week low
$6.22

Profitability

Operating margin
49.0%
Net margin
39.2%
EBITDA margin
43.8%
ROE
-344.7%
ROCE
76.8%
ROA
37.4%
Asset turnover
0.95

Growth

Revenue
$1.1B
Revenue growth, 1Y
64.7%
Revenue CAGR, 3Y
-11.1%
Net profit growth, 1Y
-334.8%
Free cash flow
-$251.0M

Solvency

Current ratio
2.13
Debt / Equity
-1.95
Debt / Assets
0.21
CFO / Net profit
-0.56
Cash / Market cap
14.4%

Where the revenue went

Of every $100 of FY2025 revenue, $39 was left as net income.

Novavax, Inc. income statement flow, FY2025
Novavax, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$73.0M
RevenueGross profit$1.1B
Gross profitResearch and development$342.3M
Gross profitSelling, general and administrative$157.5M
Gross profitOther operating expenses$0.00
Gross profitOperating income$550.6M
Operating incomePretax income$442.2M
Operating incomeInterest and other expense$108.5M
Pretax incomeTax and other$1.9M
Pretax incomeNet income$440.3M

Revenue and net profit

Revenue grew 64.7% in FY2025; net profit is the dashed line.

Novavax, Inc. revenue and net profit by fiscal year
Novavax, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.6B-$657.9M
FY2023$556.4M-$545.1M
FY2024$682.2M-$187.5M
FY2025$1.1B$440.3M

Cash flows

FY2025: -$244.6M from operations, -$251.0M free after investment (dashed).

Novavax, Inc. operating and free cash flow by fiscal year
Novavax, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$415.9M-$508.9M
FY2023-$714.0M-$772.8M
FY2024-$87.3M-$101.9M
FY2025-$244.6M-$251.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.1B+64.7%1Y
EBITDA
$492.3M
Net profit
$440.3M
Cash from operations
-$244.6M
Free cash flow
-$251.0M
Revenue CAGR, 3Y
-11.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.1B$492.3M$440.3M-$251.0M-344.7%+64.7%-334.8%

Monthly returns

Month-by-month returns of NVAX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.2B
Liabilities$1.3B
Equity-$127.8M
Paid-in capital$4.5B
Retained earnings-$4.6B
Treasury stock$103.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NVAX highlighted.

P/E against peers

NVAX trades at 3.8x earnings against a peer median of -9.8x.

  1. Novavax, Inc. (this company)3.8x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Biohaven Ltd., Sionna Therapeutics, Inc., Palvella Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Novavax, Inc.NVAXthis company$1.7B3.8x-13.1x-344.7%3.4x
Biohaven Ltd.BHVN$1.7B-2.3x33.0x-1418.8%-2.4x
Agios Pharmaceuticals, Inc.AGIO$1.7B-4.1x1.4x-34.6%-3.6x
Sionna Therapeutics, Inc.SION$1.7B-22.7x5.6x-24.5%-18.7x
Taysha Gene Therapies, Inc.TSHA$1.7B-15.5x6.9x-44.1%-13.4x
Addus HomeCare CorporationADUS$1.7B17.5x1.5x8.8%11.2x
GeneDx Holdings Corp.WGS$1.7B-79.5x5.4x-6.8%138.2x
Palvella Therapeutics, Inc.PVLA$1.6B-39.5x58.9x-149.1%-44.3x
Innoviva, Inc.INVA$1.6B6.0x1.4x23.1%3.7x
Peer median—-9.8x5.5x-29.6%-3.0x

Year-to-date ROI

NVAX since 1 January, against earlier years.

Historical volatility

NVAX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Novavax, Inc. operating margin by fiscal year
Novavax, Inc. operating margin by fiscal year
DateOperating margin
FY2022-40.3%
FY2023-101.8%
FY2024-36.5%
FY202549.0%
LineFY2025
Cost of revenueCost Of Revenue$73.0M
Gross profitGross Profit$1.1B
Operating expensesOperating Expense$499.8M
Research and developmentResearch And Development$342.3M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$572.8M
Pretax incomePretax Income$442.2M

Learn while you research

Academy chapters picked for Novavax, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 3.8 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing65% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →